| STUDY TYPE (EN) | LOCATION (EN) | COMPANY (EN) | BRANCH (EN) | INVESTIGATOR | PHASE (EN) | STUDY TITLE (EN) | STATUS (EN) | LINK (EN) |
|---|---|---|---|---|---|---|---|---|
| CLINICAL TRIAL | IZMIR MPH | NOVARTIS SAGLIK GIDA VE TARIM URUNLERI SAN. VE TIC. A.S. | NEUROLOGY | PROF DR SERKAN OZAKBAS | PHASE 3 | A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension | ONGOING | https://clinicaltrials.gov/study/NCT04926818 |
| CLINICAL TRIAL | IZMIR MPH | NOVARTIS SAGLIK GIDA VE TARIM URUNLERI SAN. VE TIC. A.S. | NEUROLOGY | PROF DR SERKAN OZAKBAS | PHASE 3 | An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | ONGOING | https://clinicaltrials.gov/study/NCT03650114 |
| CLINICAL TRIAL | IZMIR MPH | NOVARTIS SAGLIK GIDA VE TARIM URUNLERI SAN. VE TIC. A.S. | NEUROLOGY | PROF DR SERKAN OZAKBAS | PHASE 3 | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | ONGOING | https://clinicaltrials.gov/study/NCT05156281 |
| CLINICAL TRIAL | IZMIR MPH | NOVONORDISK | NEUROLOGY | PROF DR OZGE YILMAZ KUSBECI | PHASE 3 | A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus) | ONGOING | https://clinicaltrials.gov/study/NCT04777409 |
| CLINICAL TRIAL | IZMIR MPH | NOVONORDISK | NEUROLOGY | PROF DR OZGE YILMAZ KUSBECI | PHASE 3 | A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE) | ONGOING | https://clinicaltrials.gov/study/NCT04777396 |
| CLINICAL TRIAL | IZMIR MPH | PPD GLOBAL LIMITED | NEUROLOGY | DOC DR HALIL GULLUOGLU | PHASE 3 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease | ONGOING | https://clinicaltrials.gov/study/NCT06585787 |
| STUDY TYPE (EN) | LOCATION (EN) | COMPANY (EN) | BRANCH (EN) | INVESTIGATOR | PHASE (EN) | STUDY TITLE (EN) | STATUS (EN) | LINK (EN) |
| STUDY TYPE (EN) | LOCATION (EN) | COMPANY (EN) | BRANCH (EN) | INVESTIGATOR | PHASE (EN) | STUDY TITLE (EN) | STATUS (EN) | LINK (EN) |
|---|---|---|---|---|---|---|---|---|
| CLINICAL TRIAL | IZMIR MPH | PPD GLOBAL LIMITED | NEUROLOGY | PROF DR OZGE YILMAZ KUSBECI | PHASE 3 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease | COMPLETED | https://clinicaltrials.gov/study/NCT06126224 |
| CLINICAL TRIAL | IZMIR MPH | PPD GLOBAL LIMITED | NEUROLOGY | PROF DR OZGE YILMAZ KUSBECI | PHASE 3 | Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT and KarXT + KarX-EC in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | COMPLETED | https://clinicaltrials.gov/study/NCT05980949 |
| STUDY TYPE (EN) | LOCATION (EN) | COMPANY (EN) | BRANCH (EN) | INVESTIGATOR | PHASE (EN) | STUDY TITLE (EN) | STATUS (EN) | LINK (EN) |
Researchers
{"cpt":"team","style":"2","columns":"3","show":"6","from_category":["neurology"],"order":"DESC","orderby":"none"}
